Premium
Concentration‐time profile for perhexiline and hydroxyperhexiline in patients at steady state
Author(s) -
Jones Terry E.,
Morris Raymond G.,
Horowitz John D.
Publication year - 2004
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.2003.02003.x
Subject(s) - concomitant , medicine , cyp2d6 , plasma concentration , pharmacokinetics , pharmacology , endocrinology , metabolism , cytochrome p450
Aim To define inter‐ and intraday variability in plasma perhexiline concentrations, time‐to‐maximum plasma perhexiline concentration and variability in the ratio of hydroxyperhexiline to parent perhexiline concentrations over the course of the day in patients at steady state. Methods Eight blood samples were taken over a 24‐h period from 12 adult patients already taking perhexiline for the treatment of angina pectoris. These patients were assumed to be at steady state, having taken the same dose of perhexiline for more than 4 weeks and having no changes made to other drug therapy that might have affected plasma perhexiline concentrations (especially drugs that interfere with CYP2D6). Perhexiline was assayed by HPLC/FL. The percentage increase over baseline concentration was determined for each patient for both perhexiline and hydroxyperhexiline. Results Trough plasma perhexiline concentrations from two patients were below the limit of quantification of the assay (0.05 mg l −1 ) and thus were excluded from the analysis. The greatest mean percentage increase in plasma perhexiline concentration over the day was 21% (95%CI 9%, 33%, range −19% to 45%) which occurred 6 h postdose. The greatest mean percentage increase in plasma hydroxyperhexiline concentration was 10.8% (95%CI −5.3%, 26.9%, range −13% to 60%) which occurred 4 h postdose. However individual patients demonstrated > 60% intraday variability in perhexiline concentrations which was not related to the concomitant use of drugs that affect CYP2D6 activity. Changes in random plasma perhexiline concentration which are attributed to changes in concomitant drug therapy should be supported by additional kinetic data. Inter‐day variability in plasma perhexiline concentration as determined by the ratio of C 24 : C 0 was small (mean 0.90, 95%CI 0.77, 1.03) which supports C 0 as the best sampling time for perhexiline concentration monitoring. The variability in C 24 : C 0 for hydroxyperhexiline concentrations was smaller (mean 0.96, 95%CI 0.81, 1.11). Variability in the ratio of plasma concentrations of hydroxyperhexiline to perhexiline over the day was also small. The ratio of plasma hydroxyperhexiline to perhexiline concentration over the day fell within a narrow range for all subjects with 95% confidence intervals being < 15% for eight patients and < 25% for the remaining patient. This suggests that formation of the metabolite occurs rapidly and may be presystemic. It also supports the calculation of the hydroxyperhexiline : perhexiline ratio (in patients at steady state) on blood samples taken at any time during the dosing interval. Conclusions The within‐day variability in plasma perhexiline concentrations was small. While C 0 is probably the best time for therapeutic drug monitoring purposes, it is not unreasonable to use samples drawn at any time during the dosing interval. The therapeutic range used in this hospital (0.15–0.6 mg l −1 ) was devised from earlier work using 4 h postdose blood sampling which is close to the ‘peak’ concentration and a mean of 16% higher than C 0 in this study. This increase is probably clinically insignificant and a different C 0 range is therefore not warranted.